OBJECTIVES: The aim of this study was to describe the health related quality of life (HRQoL) in different breast cancer disease states using preference-based measures. MATERIAL AND METHODS: A total of 361 consecutive breast cancer patients attending the breast cancer outpatient clinic at Karolinska University hospital Solna for outpatient visits between April and May 2005 were included in the study. The EQ-5D self classifier and a direct Time Trade Off (TTO) question were used to estimate the HRQoL in different breast cancer disease states. RESULTS: Patients in their first year after a primary breast cancer had a mean EQ-5D index value of 0.696 (95% confidence interval (CI): 0.634-0.747)). Patients in their first year after a recurrence had a mean EQ-5D index value of 0.779 (CI: 0.700-0.849). Patients who had not had a primary breast cancer diagnosis or a recurrence during the previous year had a mean EQ-5D index value of 0.779 (CI: 0.745-0.811). Patients with metastatic disease reported the lowest HRQoL values, and had a mean EQ-5D index value of 0.685 (CI: 0.620-0.735). The main driver behind the reduction in HRQoL was pain and discomfort as well as anxiety and depression. TTO values were higher for all diseases states compared to the EQ-5D index values. CONCLUSION: This study shows that breast cancer is associated with a reduction in HRQoL. This effect is most pronounced for patients with metastatic disease.
OBJECTIVES: The aim of this study was to describe the health related quality of life (HRQoL) in different breast cancer disease states using preference-based measures. MATERIAL AND METHODS: A total of 361 consecutive breast cancerpatients attending the breast canceroutpatient clinic at Karolinska University hospital Solna for outpatient visits between April and May 2005 were included in the study. The EQ-5D self classifier and a direct Time Trade Off (TTO) question were used to estimate the HRQoL in different breast cancer disease states. RESULTS:Patients in their first year after a primary breast cancer had a mean EQ-5D index value of 0.696 (95% confidence interval (CI): 0.634-0.747)). Patients in their first year after a recurrence had a mean EQ-5D index value of 0.779 (CI: 0.700-0.849). Patients who had not had a primary breast cancer diagnosis or a recurrence during the previous year had a mean EQ-5D index value of 0.779 (CI: 0.745-0.811). Patients with metastatic disease reported the lowest HRQoL values, and had a mean EQ-5D index value of 0.685 (CI: 0.620-0.735). The main driver behind the reduction in HRQoL was pain and discomfort as well as anxiety and depression. TTO values were higher for all diseases states compared to the EQ-5D index values. CONCLUSION: This study shows that breast cancer is associated with a reduction in HRQoL. This effect is most pronounced for patients with metastatic disease.
Authors: Timothy J Whelan; Paul E Goss; James N Ingle; Joseph L Pater; Dongsheng Tu; Kathleen Pritchard; Shifang Liu; Lois E Shepherd; Michael Palmer; Nicholas J Robert; Silvana Martino; Hyman B Muss Journal: J Clin Oncol Date: 2005-09-12 Impact factor: 44.544
Authors: S Chan; K Friedrichs; D Noel; T Pintér; S Van Belle; D Vorobiof; R Duarte; M Gil Gil; I Bodrogi; E Murray; L Yelle; G von Minckwitz; S Korec; P Simmonds; F Buzzi; R González Mancha; G Richardson; E Walpole; M Ronzoni; M Murawsky; M Alakl; A Riva; J Crown Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Adam R Kendall; Maya Mahue-Giangreco; Catherine L Carpenter; Patricia A Ganz; Leslie Bernstein Journal: Qual Life Res Date: 2005-03 Impact factor: 4.147
Authors: L Masucci; S Torres; A Eisen; M Trudeau; I Tyono; H Saunders; K W Chan; W Isaranuwatchai Journal: Curr Oncol Date: 2019-10-01 Impact factor: 3.677
Authors: Helena Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Daniel Rea; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Sophie Gasson; Claire Balmer; Jean E Abraham; Carlos Caldas; Peter Hall; Bethany Shinkins; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn Journal: Health Technol Assess Date: 2020-08 Impact factor: 4.014
Authors: Janne C Mewes; Lotte M G Steuten; Saskia F A Duijts; Hester S A Oldenburg; Marc van Beurden; Martijn M Stuiver; Myra S Hunter; Jacobien M Kieffer; Wim H van Harten; Neil K Aaronson Journal: J Cancer Surviv Date: 2014-09-02 Impact factor: 4.442
Authors: Jennifer A Shin; Areej El-Jawahri; Amanda Parkes; Stephen M Schleicher; Helen P Knight; Jennifer S Temel Journal: J Palliat Med Date: 2016-04-28 Impact factor: 2.947